Frequency Therapeutics Inc. (NASDAQ:FREQ) went up by 4.63% from its latest closing price compared to the recent 1-year high of $58.37. The company’s stock price has collected 23.50% of gains in the last five trading sessions. Press Release reported 21 hours ago that SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Frequency Therapeutics, Inc. – FREQ
Is It Worth Investing in Frequency Therapeutics Inc. (NASDAQ :FREQ) Right Now?
Opinions of the stock are interesting as 4 analysts out of 5 who provided ratings for Frequency Therapeutics Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 1 as “sell.”
The average price from analysts is $19.75. FREQ currently public float of 26.29M and currently shorts hold a 15.84% ratio of that float. Today, the average trading volume of FREQ was 1.08M shares.
FREQ’s Market Performance
FREQ stocks went up by 23.50% for the week, with a monthly drop of -73.07% and a quarterly performance of -70.00%, while its annual performance rate touched -33.87%. The volatility ratio for the week stands at 10.92% while the volatility levels for the past 30 days are set at 11.36% for Frequency Therapeutics Inc.. The simple moving average for the period of the last 20 days is -59.59% for FREQ stocks with a simple moving average of -64.43% for the last 200 days.
Analysts’ Opinion of FREQ
Many brokerage firms have already submitted their reports for FREQ stocks, with JP Morgan repeating the rating for FREQ by listing it as a “Overweight.” The predicted price for FREQ in the upcoming period, according to JP Morgan is $56 based on the research report published on January 27th of the current year 2021.
B. Riley Securities, on the other hand, stated in their research note that they expect to see FREQ reach a price target of $79. The rating they have provided for FREQ stocks is “Buy” according to the report published on December 22nd, 2020.
Oppenheimer gave a rating of “Outperform” to FREQ, setting the target price at $36 in the report published on July 14th of the previous year.
FREQ Trading at -73.81% from the 50-Day Moving Average
After a stumble in the market that brought FREQ to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -82.76% of loss for the given period.
Volatility was left at 11.36%, however, over the last 30 days, the volatility rate increased by 10.92%, as shares sank -71.28% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -74.01% lower at present.
During the last 5 trading sessions, FREQ rose by +23.50%, which changed the moving average for the period of 200-days by -54.87% in comparison to the 20-day moving average, which settled at $23.66. In addition, Frequency Therapeutics Inc. saw -71.45% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at FREQ starting from Lucchino David L., who sale 9,416 shares at the price of $50.43 back on Mar 01. After this action, Lucchino David L. now owns 308,086 shares of Frequency Therapeutics Inc., valued at $474,836 using the latest closing price.
Lucchino David L., the President and CEO of Frequency Therapeutics Inc., sale 16,554 shares at $55.00 during a trade that took place back on Feb 08, which means that Lucchino David L. is holding 308,086 shares at $910,470 based on the most recent closing price.
Stock Fundamentals for FREQ
Current profitability levels for the company are sitting at:
- -74.49 for the present operating margin
- +95.73 for the gross margin
The net margin for Frequency Therapeutics Inc. stands at -71.68. The total capital return value is set at -13.58, while invested capital returns managed to touch -13.08. Equity return is now at value -14.80, with -11.50 for asset returns.
Based on Frequency Therapeutics Inc. (FREQ), the company’s capital structure generated 23.89 points at debt to equity in total, while total debt to capital is 19.29. Total debt to assets is 17.37, with long-term debt to equity ratio resting at 23.69. Finally, the long-term debt to capital ratio is 19.12.
When we switch over and look at the enterprise to sales, we see a ratio of 26.04, with the company’s debt to enterprise value settled at 0.05. The receivables turnover for the company is 64.60 and the total asset turnover is 0.15. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.45.